# Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

> **NCT00019682** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 185 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIA Skin Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** gp100 Antigen
- **DRUG:** Montanide ISA 51 VG
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00019682
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019682, "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00019682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*